Thursday, March 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Key Patent Awarded for Synthetic Saponin Vaccine Adjuvant

by Global Biodefense Staff
November 15, 2012

The United States Patent and Trademark Office has granted the co-founders of Adjuvance Technologies, Inc., a patent for a pioneering invention which provides a novel synthetic method to produce saponin adjuvants including QS-21, a leading vaccine adjuvant currently used in advanced clinical trials for infectious disease, neurodegenerative disorders and oncology. 

Despite the critical ability of adjuvants to improve the immune response to vaccine antigens, there are very few adjuvants approved for human use in the U.S. 

One of the most widely used and potent immunological adjuvants is a mixture of soluble triterpene glycosides purified from the soap bark tree (Quillaja saponaria). Despite challenges in production, quality control, stability and toxicity, this extract exhibits exceptional adjuvant properties for a range of antigens. 

Adjuvance’s new patented technology providing an ecologically sustainable synthetic product of the active molecules of QS-21 that is extremely dependable and scalable. This ability provides a robust method to produce this leading vaccine adjuvant in high purity as well as to produce novel synthetic QS-21 congeners designed to induce increased immune responsiveness and decreased toxicity. 

“We believe this technology, which was developed at the Sloan-Kettering Institute of Memorial Sloan-Kettering Cancer Center, represents a fundamental breakthrough in vaccine adjuvant design and manufacturing,” said Jeffrey Gardner, Adjuvance Technologies‘ CEO and co-founder. “Before this innovative approach to producing saponin adjuvants, tedious isolation and purification protocols were necessary to obtain these materials. This work will greatly facilitate access to these promising molecules for investigators and vaccine developers.” 

As exclusive licensee of the technology, Adjuvance will continue to focus on the commercial development of saponin adjuvants for use in innovative therapeutic and prophylactic human vaccines as well as pandemic preparedness and biodefense efforts.

Tags: AwardsVaccines

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC